A carregar...
Natalizumab for the treatment of relapsing multiple sclerosis
Natalizumab is an α4-integrin antagonist approved as monotherapy for patients with relapsing multiple sclerosis (MS), based on demonstrated efficacy in the pivotal AFFIRM study (N = 942). Natalizumab monotherapy reduced risk of disability progression by 42%–54% and annualized relapse rate by 68% dur...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2721353/ https://ncbi.nlm.nih.gov/pubmed/19707353 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|